Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminase

Chinese Journal of Digestive Diseases

Volumn 3, Issue 4, 2002, Pages 150-153

  Yang, Liu Ming ^a   Xu, Ke Cheng ^b   Zhao, Yan Long ^a   Wu, Zhi Rong ^a   Chen, Tu Fang ^a   Qin, Zhuo Ying ^a   Zuo, Jian Sheng ^c   Wei, Bei Hai ^d  

^a Hepatol Sec Lianjiang Peoples Hosp   (China)

^b Shenzhen University   (China)

^c Shenzhen Young Hearty Medical Center   (China)

^d Beijing Institute of Chinese Medicine   (China)

Author keywords

Chronic hepatitis B; Hepatic histology; Hepatitis B virus infection; Liver biopsy

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LIVER ENZYME; PREDNISONE; RIBAVIRIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATHOLOGIST; PERCUTANEOUS BIOPSY; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT PLANNING;

EID: 0036999977     PISSN: 14439611     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1443-9573.2002.00093.x     Document Type: Article

References (13)

1. Lau GKK, Carman WF, Locarnini SA et al. Treatment of chronic hepatitis B Virus infection: An Asia-Pacific perspective. J Gastroenterol Hepatol 1999; 14: 3-11.
2. Xu KC, Wei BH, Yao XX et al. Modern treatment of chronic hepatitis B. Chin J Gastroenterol Hepatol 1999; 8: 301-5 (in Chinese).
3. Malik AH, Lee WM. Chronic hepatitis B virus infection: Treatment Strategies for the next millennium. Ann Intern Med 2000; 132: 723-5.
4. Chinese Medical Association, Infectious and Parasitic Disease, and Hepatology Branches. Prevention and treatment of viral hepatitis. Chin J Hepatol 2000; 8: 324-9 (in Chinese).
5. Healey CJ, Chapman RWG, Fleming KA. Liver histology in hepatitis C infection: A comparison between patients with persistently normal or abnormal transaminases. Gut 1995; 37: 274-8.
6. Kyrlagkitsis I, Portmann B, Cramp ME. Liver histology and progression of fibrosis in individuals with chronic C virus infection and persistently normal ALT. Hepatology 2000; 34: 285-91.
7. Boni C, Penna A, Ogg GS et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy. Hepatology 2001; 33: 967-71.
8. Moseley RH. Approach to the patients with abnormal liver chemistries. In: Yamada T, Alpers DH, Laine L, Owyang C, Powell DW (eds) Textbook of Gastroenterology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, 1999; 946-65.
9. Huo T, Wu JC, Hwang SJ et al. Factors predictive of liver cirrhosis in patients with chronic hepatitis B: A multivariate analysis in a longitudinal study. Eur J Gastroenterol Hepatol 2000; 12: 687-93.
10. Lee SS, Sherman M. Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values. J Viral Hepatol 2001; 8: 202-5.
11. Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000; 32: 604-9.
12. Chun YK, Kim JY, Woo HJ et al. No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection. Hepatology 2000; 32: 1154-62.
13. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33: 196-200.